{
  "Variants Include": [
    {
      "Gene": "SNCA",
      "variants": [
        {
          "HGVS": "NM_001126112.3:c.90A>T",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "A",
            "alt": "T",
            "position": "90"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "P",
            "position": "30"
          },
          "Description in input context": "A30P"
        },
        {
          "HGVS": "NM_001126112.3:c.158A>T",
          "cDNA Change": {
            "transcript": "NM_001126112.3",
            "ref": "A",
            "alt": "T",
            "position": "158"
          },
          "Protein Change": {
            "ref": "A",
            "alt": "T",
            "position": "53"
          },
          "Description in input context": "A53T"
        }
      ]
    }
  ],
  "Described Disease": {
    "Described Disease": "Parkinson's disease",
    "MONDO": "MONDO:0005225"
  },
  "Experiment Method": [
    {
      "Assay Method": "PLD2 inhibition assay",
      "Material used": {
        "Material Source": "Recombinant proteins",
        "Material Name": "Synuclein isoforms and mutants",
        "Description": "Recombinant synuclein proteins (wild-type and mutants) were used to test PLD2 inhibition activity."
      },
      "Readout type": "Quantitative",
      "Readout description": [
        {
          "Variant": "NM_001126112.3:c.90A>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Enhanced PLD2 inhibition",
          "Result Description": "A30P mutant showed significantly higher PLD2 inhibition compared to wild-type."
        },
        {
          "Variant": "NM_001126112.3:c.158A>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Enhanced PLD2 inhibition",
          "Result Description": "A53T mutant exhibited stronger PLD2 inhibition than wild-type."
        },
        {
          "Variant": "NM_001126112.3:c.90A>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Phosphorylation-sensitive",
          "Result Description": "Phosphorylation of A30P reduced PLD2 inhibition activity."
        },
        {
          "Variant": "NM_001126112.3:c.158A>T",
          "Conclusion": "Abnormal",
          "Molecular Effect": "Phosphorylation-sensitive",
          "Result Description": "Phosphorylation of A53T altered PLD2 inhibition dynamics."
        }
      ],
      "Biological replicates": {
        "Biological replicates": "N.D.",
        "Description": "Not explicitly mentioned in the text."
      },
      "Technical replicates": {
        "Technical replicates": "N.D.",
        "Description": "Not explicitly mentioned in the text."
      },
      "Basic positive control": {
        "Basic positive control": "Yes",
        "Description": "Wild-type synuclein proteins served as positive controls."
      },
      "Basic negative control": {
        "Basic negative control": "Yes",
        "Description": "Phosphorylation-deficient mutants were used as negative controls."
      },
      "Validation controls P/LP": {
        "Validation controls P/LP": "N.D.",
        "Counts": "N.D."
      },
      "Validation controls B/LB": {
        "Validation controls B/LB": "N.D.",
        "Counts": "N.D."
      },
      "Statistical analysis method": {
        "Statistical analysis method": "N.D.",
        "Description": "Not explicitly mentioned in the text."
      },
      "Threshold for normal readout": {
        "Threshold for normal readout": "PLD2 inhibition activity within baseline range of wild-type proteins.",
        "Source": "Custom"
      },
      "Threshold for abnormal readout": {
        "Threshold for abnormal readout": "PLD2 inhibition activity exceeding 20% of wild-type baseline.",
        "Source": "Custom"
      },
      "Approved assay": {
        "Approved assay": "Yes",
        "Description": "PLD2 inhibition assays are commonly used in Parkinson's disease research."
      }
    }
  ]
}